| Description | Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, thereby disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses, as well as related innate and adaptive immunity pathways [1] [2]. |
| In vitro | Orilanolimab (10nM、50nM及100nM；48小时) 在 B2M TG/TG FCGRT TG/TG Fcgrt-/- 小鼠模型中，显著抑制CD11c^+ IFN-γ的产生[1]。 |
| In vivo | Orilanolimab（20mg/kg；静脉注射）在小鼠模型中显著降低了HuLys11的血浆浓度[1]。不同剂量的Orilanolimab（10-100 mg/kg；静脉注射；每5周一次）在IgG食蟹猴中引起了剂量依赖性和特异性的总循环水平下降[1]。 |
| Synonyms | SYNT001 |
| molecular weight | N/A |
| CAS | 2066544-85-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |